Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Immunovia AB's Enterprise Value is kr73.54 Mil.
Immunovia AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was kr-79.40 Mil. Therefore, Immunovia AB's EV-to-EBIT ratio for today is -0.93.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Immunovia AB's Enterprise Value is kr73.54 Mil.
Immunovia AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was kr-77.93 Mil. Therefore, Immunovia AB's EV-to-EBITDA ratio for today is -0.94.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Immunovia AB's Enterprise Value is kr73.54 Mil.
Immunovia AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.92 Mil. Therefore, Immunovia AB's EV-to-Revenue ratio for today is 80.03.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Immunovia AB's Enterprise Value is kr73.54 Mil.
Immunovia AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was kr-74.93 Mil. Therefore, Immunovia AB's EV-to-FCF ratio for today is -0.98.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Immunovia AB (OSTO:IMMNOV) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Immunovia AB's current Enterprise Value is kr73.54 Mil.
Immunovia AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-79.40 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Immunovia AB's current Enterprise Value is kr73.54 Mil.
Immunovia AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-77.93 Mil.
Immunovia AB's current Enterprise Value is kr73.54 Mil.
Immunovia AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.92 Mil.
Immunovia AB's current Enterprise Value is kr73.54 Mil.
Immunovia AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-74.93 Mil.
Immunovia AB's current Enterprise Value is kr73.54 Mil.
Immunovia AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-74.93 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immunovia AB Enterprise Value Related Terms
Immunovia AB Enterprise Value Historical Data
* Premium members only.
The historical data trend for Immunovia AB's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:IMMNOV vs TMO, DHR, IDXX: Enterprise Value Comparison
For the Diagnostics & Research subindustry, Immunovia AB's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immunovia AB Enterprise Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Immunovia AB's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Immunovia AB's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Immunovia AB's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immunovia AB (OSTO:IMMNOV) has a Enterprise Value of kr73.54 Mil as of Jul. 03, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Immunovia AB and its competitors.
Is Immunovia AB's Enterprise Value too high?
Immunovia AB's current Enterprise Value is kr73.54 Mil. Overall, Immunovia AB has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Immunovia AB's Enterprise Value compare to TMO and DHR?
Immunovia AB's Enterprise Value of kr73.54 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Diagnostics & Research company?
A good Enterprise Value depends on the Medical Diagnostics & Research industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Immunovia AB and its competitors. Immunovia AB's current Enterprise Value is kr73.54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunovia AB stock overvalued right now?
Based on GuruFocus' analysis, Immunovia AB (OSTO:IMMNOV) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.07, compared to a current price of kr0.19 — trading 174.3% above its estimated fair value. The current Enterprise Value is kr73.54 Mil. Immunovia AB's overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Immunovia AB (OSTO:IMMNOV), the current Enterprise Value is kr73.54 Mil as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immunovia AB (OSTO:IMMNOV) Overvalued in 2026?
Based on GuruFocus' analysis, Immunovia AB stock appears to be overvalued.
The current stock price of kr0.19 is trading 174.3% above its estimated GF Value™ of kr0.07.
GuruFocus considers Immunovia AB to be Significantly Overvalued.
Key valuation signals for OSTO:IMMNOV:
Enterprise Value: kr73.54 Mil
GF Value™: kr0.07 vs. price of kr0.19 (174.3% above fair value)
No single metric tells the full story. See the OSTO:IMMNOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immunovia AB is a diagnostic company. The company develops and commercializes diagnostic tools to detect proteins and autoimmune diseases. The company is developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer. Its technology platform IMMray (TM), is based on antibody microarray analysis.
44GF Score
Get the complete analysis for OSTO:IMMNOV
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:IMMNOV has been successfully added to your 
